Analysis of the relation between the KRAS mutational status and clinicopathological characteristics in the patients revealed that the presence or absence of KRAS mutations was not related to the sex of patients (p = 0.507), patients’ age at the time of testing (p = 1.000), histological type of tumor (p = 0.128), and simultaneous distant and lymph node metastasis (p = 0.471), while wild-type KRAS patients had more rare distant metastasis in comparison with patients with KRAS mutations (0.35, 95% CI: 0.19–0.64, p = 0.006, Table 5). This evidence concerns the gene KRAS and metastatic malignant neoplasm in the lymph nodes.